Correvio Pharma Corp.
https://correvio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Correvio Pharma Corp.
Deal Watch: Roche To Try Pieris’s Anticalins In Respiratory, Ophthalmic Indications
Pieris and Genentech try partnering again after a disappointing IO tie-up before. Biogen’s hectic May includes partnerships with Ginkgo, Envisagenics, Capsigen and an opt-in on TMS’s stroke candidate.
Neurocrine Not Giving Up On Luvadaxistat Despite Phase II Miss
Schizophrenia drug licensed from Takeda missed Phase II endpoint for negative symptoms, but hits secondary cognition endpoints. Neurocrine plans to further study compound for cognitive benefits.
MedLumics Closes $21.7M Financing To Support Optically Guided Ablation Catheter
The Madrid, Spain-based company is developing the AblaView ablation catheter for treating atrial fibrillation.
PTC Eyes Transition From Capital-Raising To Money-Making Company
With $1.1bn in cash plus revenue from its existing commercial products and royalties from Roche’s sales of newly approved Evrysdi to invest in R&D, PTC Therapeutics may achieve profitability in 2023.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- ADVANZ PHARMA Corp. Limited
- Cardiome Pharma Corp. (CRME)
- Cardiome Development AG
- Correvio LLC (Iroko Cardio LLC)